Cited 45 times in
Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.